High-dose calcitriol and docetaxel, each given separately one day a week for six weeks, appear to be an effective and well-tolerated combination for men living with metastatic hormone-refractory prostate cancer (HRPC) previously treated with docetaxel-based chemotherapy, Italian investigators conclude.